Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy

被引：24

作者：

Lambert-Niclot, Sidonie ^{[1
,2
]}

Peytavin, Gilles ^{[3
,4
]}

Duvivier, Claudine ^{[5
,6
]}

Poirot, Catherine ^{[7
]}

Algarte-Genin, Michele ^{[8
]}

Pakianather, Sophie ^{[8
]}

Meynard, Jean-Luc ^{[9
]}

Valantin, Marc-Antoine ^{[2
,10
]}

Molina, Jean-Michel ^{[11
]}

Flandre, Philippe ^{[1
,2
,8
]}

Katlama, Christine ^{[2
,10
]}

Calvez, Vincent ^{[1
,2
]}

Marcelin, Anne-Genevieve ^{[1
,2
]}

机构：

[1] Univ Paris 06, Pitie Salpetriere Hosp, AP HP, Dept Virol, F-75013 Paris, France

[2] INSERM, U943, Paris, France

[3] Bichat Claude Bernard Hosp, AP HP, Dept Clin Pharm, Paris, France

[4] Univ Paris 07, EA 449, Paris, France

[5] Univ Rene Descartes Paris 4, Hop Necker Enfants Malad, AP HP, Ctr Infectiol Necker Pasteur, Paris, France

[6] Ctr Med Inst Pasteur, Inst Pasteur, Paris, France

[7] Univ Paris 06, Pitie Salpetriere Hosp, AP HP, UF Biol Reprod, F-75013 Paris, France

[8] INSERM, UMR S 943, Paris, France

[9] St Antoine Hosp, AP HP, Dept Infect Dis, Paris, France

[10] Hop La Pitie Salpetriere, AP HP, Dept Infect Dis, Paris, France

[11] St Louis Hosp, AP HP, Dept Infect Dis, Paris, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2010年 / 54卷 / 11期

关键词：

TYPE-1 PROTEASE INHIBITOR; ANTIRETROVIRAL THERAPY; HIV-1-INFECTED MEN; GENITAL-TRACT; PLASMA; SAFETY; LOPINAVIR/RITONAVIR; EFFICACY; TMC114; BLOOD;

D O I：

10.1128/AAC.00725-10

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

HIV-1 RNA level and darunavir concentration in the genital tract were measured in 45 men receiving darunavir-ritonavir mono-or tritherapy. At week 48, a low frequency (3/45) of HIV-1 RNA shedding was observed in patients (1 on monotherapy and 2 on triple therapy), although they had undetectable HIV-1 RNA in plasma. The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract.

引用

页码：4910 / 4913

页数：4

共 8 条

[1] Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 Substudy
Valantin, M. A.
Kolta, S.
Flandre, P.
Genin, M. Algarte
Meynard, J. L.
Ponscarme, D.
Slama, L.
Cuzin, L.
de Kerviler, E.
Inaoui, R.
Katlama, C.
HIV MEDICINE, 2012, 13 (08) : 505 - 515
[2] High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors
Bossi, P
Peytavin, G
Lamotte, C
Calvez, V
Bricaire, F
Costagliola, D
Katlama, C
AIDS, 2003, 17 (07) : 1108 - 1110
[3] The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load <50 HIV-1 RNA copies/mL at baseline
Arribas, J. R.
Clumeck, N.
Nelson, M.
Hill, A.
van Delft, Y.
Moecklinghoff, C.
HIV MEDICINE, 2012, 13 (07) : 398 - 405
[4] Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
Calza, Leonardo
Danese, Ilaria
Magistrelli, Eleonora
Colangeli, Vincenzo
Manfredi, Roberto
Bon, Isabella
Re, Maria Carla
Conti, Matteo
Viale, Pierluigi
HIV CLINICAL TRIALS, 2016, 17 (01): : 38 - 47
[5] Effectiveness of low-dose indinavir/ritonavir at 400/100 mg twice a day with 2 nucleoside reverse transcriptase inhibitors in nonnucleoside reverse transcriptase inhibitor-experienced HIV-infected patients in India - 1-year follow-up
Patel, Atul K.
Patel, Ketan K.
Patel, Jagdish K.
Sharma, Rakesh L.
Ranjan, Rajiv R.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (01) : 123 - 126
[6] Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviraltherapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial
Cahn, Pedro
Andrade-Villanueva, Jaime
Arribas, Jose R.
Gatell, Jose M.
Lama, Jiavier R.
Norton, Michael
Patterson, Patricia
Sierra Madero, Juan
Sued, Omar
Ines Figueroa, Maria
Jose Rolon, Maria
LANCET INFECTIOUS DISEASES, 2014, 14 (07): : 572 - 580
[7] Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
Underwood, Mark
Horton, Joe
Nangle, Keith
Hopking, Judy
Smith, Kimberly
Aboud, Michael
Wynne, Brian
Sievers, Jorg
Stewart, Eugene L.
Wang, Ruolan
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (01)
[8] Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study (vol 66, e0164321, 2022)
Underwood, Mark
Horton, Joe
Nangle, Keith
Hopking, Judy
Smith, Kimberly
Aboud, Michael
Wynne, Brian
Sievers, Joerg
Stewart, Eugene L.
Wang, Ruolan
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (03)

← 1 →